PFG Investments LLC Acquires 8,800 Shares of Verona Pharma plc (NASDAQ:VRNA)

PFG Investments LLC raised its holdings in Verona Pharma plc (NASDAQ:VRNA) by 49.4% during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 26,600 shares of the company’s stock after acquiring an additional 8,800 shares during the quarter. PFG Investments LLC’s holdings in Verona Pharma were worth $428,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently bought and sold shares of the company. Adage Capital Partners GP L.L.C. grew its position in Verona Pharma by 95.1% in the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 426,931 shares of the company’s stock valued at $6,959,000 after acquiring an additional 208,100 shares during the last quarter. Wellington Management Group LLP grew its position in Verona Pharma by 3.8% in the 3rd quarter. Wellington Management Group LLP now owns 4,467,571 shares of the company’s stock valued at $72,821,000 after acquiring an additional 164,268 shares during the last quarter. American Century Companies Inc. bought a new position in Verona Pharma in the 3rd quarter valued at $4,566,000. Legato Capital Management LLC grew its position in Verona Pharma by 26.1% in the 4th quarter. Legato Capital Management LLC now owns 24,329 shares of the company’s stock valued at $484,000 after acquiring an additional 5,032 shares during the last quarter. Finally, Federated Hermes Inc. grew its position in Verona Pharma by 49.3% in the 3rd quarter. Federated Hermes Inc. now owns 2,493,530 shares of the company’s stock valued at $40,645,000 after acquiring an additional 822,832 shares during the last quarter. Institutional investors own 85.88% of the company’s stock.

Analyst Upgrades and Downgrades

VRNA has been the topic of a number of recent research reports. Wedbush reissued an “outperform” rating and set a $33.00 price target on shares of Verona Pharma in a research report on Friday, March 1st. Piper Sandler increased their price target on Verona Pharma from $31.00 to $36.00 and gave the stock an “overweight” rating in a research report on Tuesday, April 16th. Finally, HC Wainwright reissued a “buy” rating and set a $32.00 price target on shares of Verona Pharma in a research report on Monday, March 4th. Four equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $33.60.

Verona Pharma Stock Down 0.7 %

VRNA stock traded down $0.11 during trading on Tuesday, reaching $15.45. 294,733 shares of the company traded hands, compared to its average volume of 489,194. Verona Pharma plc has a 12 month low of $11.83 and a 12 month high of $23.81. The business has a 50 day simple moving average of $16.27 and a 200 day simple moving average of $16.15. The company has a market capitalization of $1.25 billion, a price-to-earnings ratio of -22.39 and a beta of 0.41. The company has a debt-to-equity ratio of 0.20, a quick ratio of 33.33 and a current ratio of 33.33.

Verona Pharma (NASDAQ:VRNA) last issued its quarterly earnings data on Thursday, February 29th. The company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.07. On average, equities research analysts anticipate that Verona Pharma plc will post -1.32 earnings per share for the current fiscal year.

Verona Pharma Company Profile

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.